July 07, 2026

Baptist Health Cancer Care to Present Research on Precision Radiation Therapy Across Complex Cancers at ASTRO 2026

Experts across Baptist Health Herbert Wertheim Cancer Institute and Eugene M. & Christine E. Lynn Cancer Institute will present new radiation oncology research and clinical expertise at the 2026 Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 26-30, 2026, in Boston.

Baptist Health South Florida

June 05, 2026

SCLC With Brain-Only Progression: Original or Substitute Systemic Therapy With or Without Brain Radiotherapy

In a Chinese retrospective cohort study reported in the Journal of Clinical Oncology, Lu et al found that adding brain radiotherapy to continued original systemic therapy produced better outcomes comp...

The ASCO Post

June 05, 2026

SCLC With Brain-Only Progression: Original or Substitute Systemic Therapy With or Without Brain Radiotherapy

In a Chinese retrospective cohort study reported in the Journal of Clinical Oncology, Lu et al found that adding brain radiotherapy to continued original systemic therapy produced better outcomes comp...

The ASCO Post

May 28, 2026

Advanced Brain Tumor Care, Close to Home

Baptist Health South Florida

April 22, 2026

First-Line Zongertinib in Advanced HER2-Mutant NSCLC

In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell...

The ASCO Post

April 22, 2026

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed...

The ASCO Post

April 22, 2026

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed...

The ASCO Post

April 22, 2026

First-Line Zongertinib in Advanced HER2-Mutant NSCLC

In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell...

The ASCO Post

April 22, 2026

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed...

The ASCO Post

April 15, 2026

Dana-Farber Research News 04.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 16 - 31.

Dana-Farber